Covid-19 con­tin­ues to be­fud­dle Big Phar­ma as Ab­b­Vie ax­es PhI of an oral drug

In the fight against Covid-19, Ab­b­Vie’s ap­proved prod­ucts and in­ves­ti­ga­tion­al as­sets have run in­to mul­ti­ple hur­dles.

The lat­est is a Phase I axe, qui­et­ly re­vealed on the fed­er­al clin­i­cal tri­als data­base in re­cent days. The Chica­go-area Big Phar­ma cit­ed “re-eval­u­a­tion of risk vs ben­e­fit (based on an­i­mal da­ta)” in an up­date to the Phase I tri­al of AB­BV-990. Ab­b­Vie had hoped the drug would work as a treat­ment for pa­tients with SARS-CoV-2, but it ap­pears it won’t make it past the 24-per­son healthy vol­un­teer study con­duct­ed in north­ern Illi­nois.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER